관련문헌 등
·Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol 2018; 17: 162？73
·손은희 등, 다발경화증의 진단: 2017 맥도널드진단기준, J Korean Neurol Assoc 36(4):273-279, 2018
·Harrison's Principles of Internal Medicine, 20e>Chapter 436: Multiple Sclerosis
·Goldman-Cecil Medicine 26th ed(2020)>CHAPTER 383 MULTIPLE SCLEROSIS AND DEMYELINATING CONDITIONS>Types of Multiple Sclerosis
·Conn's Current Therapy 2020>？ MULTIPLE SCLEROSIS
·NICE guideline; Multiple sclerosis in adults:management_Clinical guideline(Published: 8 October 2014)
·B. Yamout, et al., Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines, Multiple Sclerosis and Related Disorders 37 (2020) 101459
·Defining the clinical course of multiple sclerosis; The 2013 revisions, Neurology® 2014;83:278？286
·National Multiple Sclerosis Society_Multiple Sclerosis
·Scolding N, et al. Association of British Neurologists :revised (2015) guidelines forprescribing disease-modifying treatments in multiple sclerosis, Pract Neurol 2015;15:273？279
·O’Connor et al, Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis, N Engl J Med 2011;365:1293-303.
·Confavreux et al, Oral terifl unomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebocontrolled, phase 3 trial, Lancet Neurol 2014; 13: 247？56
·Vermersch P et al, Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial, Multiple Sclerosis Journal 2014, Vol. 20(6) 705？716 (TENERE)
·Confavreux et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years, Multiple Sclerosis Journal 2012 18(9) 1278？89
·The IFNB Multiple Sclerosis Study Group, Interferon beta-lb is effective in relapsing-remitting - multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, NEUROLOGY 1993;43:655-661
·Gold R et al, Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis, N Engl J Med 2012;367:1098-107
·Fox et al. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. N Engl J Med 2012;367:1087-97
·Hutchinson M et al. Curr Med Res Opin. Efficacy and safety of BG-12(dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. 2014 Apr;30(4):613-27.
·J-W Hyun, W Kim et al. Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome, Multiple Sclerosis Journal 2019, Vol. 25(11) 1488？1495
·민주홍 등, 다발성경화증 시장 이해에 관한 연구, Journal of Multiple Sclerosis 8(2):19-23, 2017
·NICE guideline: Teriflflunomide for treating relapsing？remitting multiple sclerosis (Published: 22 January 2014), Beta interferons and glatiramer acetate for treating multiple sclerosis (Published: 27 June 2018), Fingolimod for the treatment of highly active relapsing？remitting multiple sclerosis (Published: 25 April 2012), Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (Published: 27 August 2014)
·Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol 2018; 17: 162？73
·손은희 등, 다발경화증의 진단: 2017 맥도널드진단기준, J Korean Neurol Assoc 36(4):273-279, 2018
·Harrison's Principles of Internal Medicine, 20e>Chapter 436: Multiple Sclerosis
·Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis-Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology, Neurology® 2018;90:777-788.
·ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis, Multiple Sclerosis Journal 2018, Vol. 24(2) 96？120
·B. Yamout, et al., Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines, Multiple Sclerosis and Related Disorders 37 (2020) 101459
·Scolding N, et al. Association of British Neurologists :revised (2015) guidelines forprescribing disease-modifying treatments in multiple sclerosis, Pract Neurol 2015;15:273？279
·김수현 등, 다발성경화증의 조기 진단 및 치료, Journal of Multiple Sclerosis 1(2):44-51, 2010
·임상적단독증후군의 임상진료지침: 1부. 평가와 진단 ; Journal of Multiple Sclerosis 7(2):29-39, 2016
·임상적단독증후군의 임상진료지침: 2부. 관리와 추적 ; Journal of Multiple Sclerosis 7(2):40-48, 2016
·L. Kappos et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes (BENEFIT), Neurology 2006;67;1242-1249
·J Kuhle, G Disanto et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study, 2015 Mult Scler;21:1013-1024
·민주홍 등, 다발성경화증 시장 이해에 관한 연구, Journal of Multiple Sclerosis 8(2):19-23, 2017